ACCME to guard names during C+I

The Board of the Accreditation Council for CME approved a new process for handling complaints on accredited providers, in which those that break the rules will not be identified unless changes in their accreditation status occur.

The approval was expected. Out of 50 responses received after a six-week comment period that ended in March, 80% favored confidentiality even after a violation is verified during the Complaints and Inquiries Process, used to investigate criticisms of activities such as commercial bias. The council also expects to issue a call for comment regarding providers' obligations to provide corrective information if an activity is found to be noncompliant.
You must be a registered member of MMM to post a comment.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.

Email Newsletters


Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.